Deposition Protocol Set in National Testosterone Lawsuits
St. Louis, MO (PRWEB) April 28, 2015 -- Attorneys handling testosterone lawsuits announce progress in pretrial proceedings for heart attack and stroke claims consolidated in the Northern District of Illinois as multidistrict litigation.* Recent court documents reflect the establishment of a deposition protocol, which will apply to all 1382 cases currently pending, as well as any cases that should be transferred into this MDL in the future, specifically governing the depositions of all generic fact witnesses, according to a recent Case Management Order, an official court document.
“The testosterone lawsuit multidistrict litigation is somewhat different from most other litigation in that the defendants include numerous companies who have developed, marketed and sold a similar product. Each plaintiff’s case addresses only one of these defendants, yet the claims against them – specifically that testosterone replacement therapies have allegedly caused patients to have heart attacks and strokes – are common across every one of these testosterone lawsuits, according to the official court documents,” explains Jim Onder of the Onder Law Firm.
According to court documents, the recent Case Management Order establishes the number of depositions that may be taken for each defendant. The numbers are as follows, according to the court documents: AbbVie/Abbott: 43, Auxilium: 34, Lilly: 31, Watson/Actavis: 22, Endo: 20, Pfizer: 8. The Order also establishes routine details such as scheduling procedures for depositions, the delivery of deposition notices, attendance stipulations for depositions, and guidelines for how the depositions will be conducted, according to court documents.
These testosterone lawsuits assert that the plaintiffs and their families were unaware of the alleged risk of heart attack from testosterone boosting drugs when their prescriptions were initiated, according to court documents. The heart attack lawsuits allege that patients were not adequately warned of significant risks posed by the drug and fell victim to aggressive advertising campaigns urging the products were safe for widespread use, according to court documents. In fact, testosterone replacement therapies have only been approved by the FDA for the treatment of men who have been diagnosed with hypogonadism, an absence of serum testosterone that is detected by a blood test and that can result in a number of other health problems, according to court documents.
Lawyers representing testosterone lawsuits nationwide with are available for consultation to persons who believe they may have legal grounds for a testosterone lawsuit. If you have lost a family member to a heart attack or other cardiac incident and believe testosterone therapies such as Androgel or Testim may have been the cause, contact testosterone lawyers handling national claims to learn about your legal rights.
The Onder Law Firm welcomes testosterone lawsuit case inquiries from law firms in regards to handling them or working as co-counsel.
About The Onder Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The pharmaceutical and medical device litigators at The Onder Law Firm have represented thousands of Americans in lawsuits against multinational conglomerates from products liability for manufacture of defective or dangerous products to deceptive advertising practices. Other firms throughout the nation often seek its experience and expertise on complex litigation. It is also a recognized leader in products liability cases such as window blind cord strangulation. The Onder Law Firm offers information from testosterone lawyers at http://www.TestimTestosteroneLawsuitCenter.com.
*MDL 2545, Testosterone Replacement Therapy Products Liability Litigation, U.S. District Court, Northern District of Illinois
Michael Gudeman, Gudeman Group, +1 314-614-8709, [email protected]
Share this article